Regeneron Pharmaceuticals (REGN) Posts Strong Q2 Revenue, Is The Upside Already Priced In?
Regeneron Pharmaceuticals (REGN) is back in focus after reporting second quarter 2026 results that showed revenue of US$4.29b, alongside a quarterly dividend declaration and a new radiopharmaceuticals collaboration with Telix Pharmaceuticals.
See our latest analysis for Regeneron Pharmaceuticals.
At a share price of US$762.63, Regeneron Pharmaceuticals has seen a 30 day share price return of 22.08% and a 1 year total shareholder return of 37.21%. This points to building momentum following recent earnings, dividend news and the Telix collaboration.
If you are looking for more ideas in a similar space, this could be a good moment to scan for other healthcare AI opportunities using the Simply Wall St screener for 41 healthcare AI stocks
With Regeneron Pharmaceuticals rallying after solid revenue figures but softer earnings per share, along with fresh income and pipeline news, are investors now paying for business progress or a swing in sentiment around the stock’s outlook on value?
Most Popular Narrative: 8.5% Undervalued
Regeneron Pharmaceuticals most followed narrative points to a fair value of $833.31 against the last close of $762.63, which frames the current rally against analyst cash flow and earnings assumptions.
Regeneron's broad and advancing pipeline, including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronextamab), genetic medicines, and obesity, positions the company to benefit from demographic-driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline-driven earnings upside.
Curious what kind of revenue path and profit profile are baked into that fair value? The narrative leans on specific growth, margin and valuation multiples that may surprise you.
Result: Fair Value of $833.31 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Regeneron Pharmaceuticals still faces key pressure points, including EYLEA competition and pricing risk, along with questions over whether elevated R&D spend will translate into commercially successful new drugs.
Find out about the key risks to this Regeneron Pharmaceuticals narrative.
Next Steps
Given the mixed signals in this Regeneron Pharmaceuticals story, it makes sense to review the underlying data yourself and act while the narrative is still forming. To see what investors view as the key positives, take a closer look at the 2 key rewards
Looking for more investment ideas beyond Regeneron Pharmaceuticals?
If you want to build on what you have learned about Regeneron Pharmaceuticals, this is a strong moment to widen your watchlist with focused stock ideas.
- Spot opportunities with attractive valuations by scanning companies highlighted in the 55 high quality undervalued stocks.
- Strengthen your income potential by reviewing businesses featured in the 9 dividend fortresses.
- Reduce portfolio stress by checking out companies identified through the 81 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com